Allakos Inc ALLK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALLK is a good fit for your portfolio.
News
-
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
-
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
Trading Information
- Previous Close Price
- $1.01
- Day Range
- $0.99–1.02
- 52-Week Range
- $0.99–5.63
- Bid/Ask
- $1.01 / $1.02
- Market Cap
- $90.32 Mil
- Volume/Avg
- 105,515 / 634,942
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 131
- Website
- https://www.allakos.com
Comparables
Valuation
|
Metric
|
ALLK
|
CLDX
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.55 | 4.82 | 3.18 |
Price/Sales | — | 260.58 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ALLK
CLDX
TYRA
Financial Strength
|
Metric
|
ALLK
|
CLDX
|
TYRA
|
|---|---|---|---|
Quick Ratio | 8.27 | 13.69 | 13.27 |
Current Ratio | 9.31 | 13.87 | 13.80 |
Interest Coverage | — | — | — |
Quick Ratio
ALLK
CLDX
TYRA
Profitability
|
Metric
|
ALLK
|
CLDX
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −45.63% | −30.49% | −22.50% |
Return on Equity (Normalized) | −58.46% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −53.25% | −32.85% | −27.79% |
Return on Assets
ALLK
CLDX
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nccshyzbm | Zmqp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dzhhccm | Lmffxhm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gyfnhkkz | Sxpqmn | $97.8 Bil | |
MRNA
| Moderna Inc | Gfknvcwr | Wqbn | $38.8 Bil | |
ARGX
| argenx SE ADR | Phmksrh | Crhf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vjqptfpm | Pmnr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ltwmrbsy | Dcsgk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vchpgrbg | Mzxqfv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cxcmwlfhnh | Nqfdny | $12.5 Bil | |
INCY
| Incyte Corp | Hcwcsst | Zrgnfly | $11.5 Bil |